Dr. Dobri Kiprov
California Pacific Medical Center, Chief of the Division of Immunotherapy
Dobri Kiprov, MD, HP is internationally recognized as a pioneer and a leading expert in the field of Therapeutic Apheresis. Dr. Kiprov. is Chief of the Division of Immunotherapy at California Pacific Medical Center in San Francisco, California and Medical Director of Apheresis Care Group (ACG).
He has worked in the field of therapeutic apheresis for more than 25 years and has published extensively on this subject. Dr. Kiprov served two terms on the American Society for Apheresis (ASFA) Board of Directors and created the first ASFA educational video program.
He is also the first physician to take and pass the Hemapheresis Practitioner Exam (ASCP).
Dr. Kiprov is the recipient of the ASFA Presidential Award for his pioneering workand numerous contributions to the field of apheresis and the Society.
Dr. Kiprov is one of the first physicians in the United States to complete a formal fellowship program in Clinical Immunology and Immunopathology (Massachusettes General Hospital and Harvard Medical School, sponsored by the NIH). Dr. Kiprov’s accomplishments in the field of Immunology are reflected in his numerous publications including the first description of new immunologically related syndromes.
With his immunology and apheresis background, Dr. Kiprov has been a part of the first trials of immunotherapy (cell therapies) and is currently involved in several projects involving cell vaccines and stem cell therapies.
Dr. Kiprov’s extensive experience with immune system disorders has led to the development of educational programs that foster immune system health and longevity through his unique approach combining appealing eating habits and physical activities.
Replacing old blood plasma with young blood plasma rejuvenates stem cells in the muscle, brain, liver, and other organs. Scientiﬁcally proven in mice, and empirically observed in humans, Dr. Kirpov’s group seeks to validate and measure how the “systemic milieu” of blood plasma governs cellular age, discover why, and develop treatment therapies to help a broad range of diseases.
Dr. Kiprov’s team was the ﬁrst in the world to demonstrate that replacing the systemic milieu restores the function of impaired immunocompetent cells in patients with autoimmune diseases. Based on this observation, he developed a model whereby alteration of this systemic milieu (which means removing senescent plasma and replacing it with factors derived from young plasma) may reset the responsible biochemical pathways to their young or old states.
Notably, their team was among the ﬁrst to demonstrate that the removal of inhibitory factors present in old plasma in humans, as in the case of autoimmune diseases, matters as much as the introduction of rejuvenating factors found in the key components of young plasma. These “senile” blood factors eﬀect the root causes of cellular decline such as inﬂammation, oxidative stress, and immune dysregulation and are responsible for nearly all age-related diseases and conditions from wrinkled skin to cancer.
Dr. Kiprov’s team proposes a proof-of-concept study that will seek to induce age reversal in group of older volunteer (human) study subjects.
Dr. Maharaj is the principal investigator of an FDA/IND clinical study whereby immune factors from young donors are harvested, the neutrophils are selected, and then infused into advanced cancer patients with the objective of inducing an immune response against the patient’s malignancy. To the best of our knowledge this is the first clinical study using young blood to treat a disease associated with aging i.e. cancer.